Multivalent Targeted Theranostic Liposomes for Chemo-resistant Aggressive CaP

Abstract

While diagnosis and treatment methods of prostate cancer (CaP) continue to improve, drug resistance pathways in advance stage disease still requires new methodologies to better identify, and treat CaP with fewer side effects for patients. The research objective was to develop new theranostic (Thx) liposomes capable of independently targeting three protein receptors expressed at different stages of advanced PCa cells for delivery of imaging and therapeutic components in a single package. The multi-valent liposomes were loaded with a therapeutic (docetaxel) and PIM1 inhibitor (SGI-1776) to resensitize docetaxel resistant cells. This approach was examined to provide a targeted delivery of encapsulated therapeutics in comparison to systemic delivery methods in vitro.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2016
Accession Number
AD1052142

Entities

People

  • Paul D Benny

Organizations

  • Washington State University

Tags

DTIC Thesaurus Topics

  • Alcohols
  • Amino Acids
  • Cells
  • Drug Resistance
  • Inhibitors
  • Lipids
  • Membrane Lipids
  • Molecules
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Resistance
  • Side Effects
  • Solid Phases
  • Synthetic Membranes
  • Targeting
  • Therapy

Fields of Study

  • Medicine

Readers

  • Medical Imaging.
  • Oncology (Cancer Research).